Home
report store
chronic kidney disease ckd pipeline insight

Chronic Kidney Disease (CKD) - Pipeline Insight, 2026

Published Date : 2026

Pages : 280

Region : Global,

Summary
TOC Table of Content
LOT
Companies
- Sample Request

Chronic Kidney Disease (CKD) Pipeline Insight

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Kidney Disease Understanding

Chronic Kidney Disease Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

Chronic kidney disease (CKD) often has no symptoms in its early stages, as the kidneys have a significant capacity to compensate for damage. However, as CKD progresses, symptoms may start to appear, including swelling or edema, chest pain, dry skin, itching or numbness, fatigue, headaches, changes in urination patterns, loss of appetite, muscle cramps, nausea, shortness of breath, sleep problems, trouble concentrating, vomiting, and weight loss. People with advanced CKD can also develop complications like anemia, bone disease, and malnutrition.

Chronic kidney disease is caused by progressive decline in all kidney functions, leading to kidney damage. During this time, there is modulation and adaptation in the still-functional glomeruli, which keeps the kidneys functioning normally for as long as possible. The remaining glomeruli, therefore, experience a rise in pressure through hyper filtration. The release of various cytokines and growth factors leads to hypertrophy and hyperplasia. At the same time, the function of the glomeruli suffers due to the excessive demands on them, leading to increased permeability and proteinuria. Increased protein concentrations in the proximal tube system are direct nephrotoxins and can further impair kidney function.

Chronic Kidney Disease (CKD) is often symptomless until severe, necessitating routine blood and urine tests for early detection. Blood tests measure serum creatinine and eGFR, with elevated levels indicating impaired kidney function. Urine tests detect protein leakage, with the Albumin-to-Creatinine Ratio (ACR) indicating the severity of albuminuria. Additional tests, such as ultrasounds, CT scans, and kidney biopsies, assess structural damage and blockages.

Chronic kidney disease (CKD) has no cure, but treatment can help slow its progression and reduce symptoms. Management includes lifestyle changes, control of diabetes and high blood pressure with medications such as ACE inhibitors, and maintaining overall kidney health. In severe cases, dialysis may be needed to remove waste products and excess fluid from the blood.

“Chronic Kidney Disease Pipeline Insight 2026” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Kidney Disease pipeline landscape is provided which includes the disease overview and Chronic Kidney Disease treatment guidelines. The assessment part of the report embraces in depth Chronic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Kidney Disease Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease.

Chronic Kidney Disease Emerging Drugs Analysis

This segment of the Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Kidney Disease Emerging Drugs

Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Chronic Kidney Disease.

Clazakizumab: CSL Behring

Clazakizumab is an investigational humanized monoclonal antibody designed to inhibit interleukin-6 (IL-6), a cytokine involved in inflammation and immune responses. By binding directly to IL-6, clazakizumab prevents its interaction with the IL-6 receptor, thereby modulating downstream inflammatory pathways. According to the company’s pipeline, the drug is being evaluated in a Phase III clinical trial for the treatment of patients with chronic kidney disease.

AP306: R1 Therapeutics/ Alebund Therapeutics

AP306 is a first-in-class pan phosphate transporter inhibitor being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. The drug works by blocking the active transport of phosphate in the gastrointestinal tract through inhibition of three key phosphate transporters — NaPi-IIb, PiT-1, and PiT-2 — representing a novel mechanism distinct from traditional phosphate binders. Unlike currently available therapies that mainly bind dietary phosphate, AP306 directly inhibits phosphate absorption and has the potential to provide rapid and effective phosphate lowering with a significantly reduced pill burden. Originally discovered by Chugai Pharmaceutical and later licensed to Alebund Pharmaceuticals, the drug was subsequently acquired by R1 Therapeutics through its acquisition of Alebund Pharmaceuticals, giving R1 Therapeutics rights to continue the development of AP306. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

MZE829: Maze Therapeutics

MZE829 is an investigational oral small-molecule therapy being developed for the treatment of APOL1 kidney disease, a genetically driven form of chronic kidney disease (CKD). The drug is designed as a selective inhibitor of APOL1, a protein associated with kidney injury and progressive renal dysfunction in individuals carrying certain APOL1 genetic variants. MZE829 works by directly inhibiting the toxic activity of APOL1 risk variants, thereby aiming to protect podocytes and reduce kidney damage, inflammation, and proteinuria. The therapy has the potential to address the underlying cause of APOL1-mediated kidney disease rather than only treating symptoms. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

PXL770: Poxel SA

PXL770 is an investigational oral direct activator of AMP-activated protein kinase (AMPK) being developed for metabolic and kidney-related disorders, including chronic kidney disease (CKD). PXL770 is designed to activate AMPK, a key regulator of cellular energy homeostasis, glucose metabolism, lipid metabolism, inflammation, and fibrosis. By directly activating AMPK, the drug aims to improve mitochondrial function, reduce lipid accumulation, suppress inflammatory and fibrotic pathways, and protect kidney function. PXL770 demonstrated beneficial effects on renal, metabolic, and inflammatory biomarkers in preclinical and clinical studies, supporting its potential as a disease-modifying therapy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Chronic Kidney Disease.

RN-032: Rege Nephro Co., Ltd.

RN-032 is an investigational cell therapy being developed for the treatment of chronic kidney disease (CKD). The therapy uses nephron progenitor cells (NPCs) derived from allogeneic human induced pluripotent stem cells (iPSCs), also referred to as iNPCs. NPCs are precursor cells that give rise to nephrons, the functional units of the kidney. RN-032 is designed to regenerate and repair damaged kidney tissue by implanting these iPSC-derived nephron progenitor cells into injured kidneys. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Chronic Kidney Disease.

Further product details are provided in the report……..

Chronic Kidney Disease Drug Therapeutic Assessment

This segment of the report provides insights about the different Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Chronic Kidney Disease Players in Chronic Kidney Disease

There are approx. 75+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. Phase III include Novo Nordisk, and others.

Chronic Kidney Disease Clinical Trial Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like:

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Chronic Kidney Disease Drug Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Chronic Kidney Disease Product Molecule Type

Products have been categorized under various molecule types such as:

Oligonucleotide
Peptide
Small molecule

Chronic Kidney Disease Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Kidney Disease Clinical Trial Activities

The Chronic Kidney Disease Pipeline report provides insights into Chronic Kidney Disease Clinical Trials within Phase II, I, preclinical and discovery stage. It also analyses Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.

Chronic Kidney Disease Pipeline Development Activities

The Chronic Kidney Disease Clinical Trial Analysis report covers detailed information on collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Kidney Disease drugs.

Chronic Kidney Disease Pipeline Report Insights

Chronic Kidney Disease Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Chronic Kidney Disease Pipeline Report Assessment

Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions Answered In The Chronic Kidney Disease Pipeline Report

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Kidney Disease drugs?
How many Chronic Kidney Disease drugs are developed by each company?
How many emerging drugs are in mid-stage and late-stage of development for the treatment of Chronic Kidney Disease?
What are the key collaborations (Industry–Industry, Industry–Academia), mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chronic Kidney Disease and their status?
What are the key designations that have been granted to the emerging drugs?